Skip to main content

Table 1 Patient characteristics at screening, data are Mean ± SEM or median [range]

From: The role of empagliflozin-induced metabolic changes for cardiac function in patients with type 2 diabetes. A randomized cross-over magnetic resonance imaging study with insulin as comparator

N

17

Sex (female/male)

4/13

Age (years)

59 [27–74]

BMI (kg/m2)

33 ± 0.7

Diabetes duration (years)

9 [2–25]

Blood pressure (mmHg)

144 ± 4/87 ± 2

History of cardiovascular disease (N)

7

HbA1c (mmol/mol)

52 ± 3

Fasting blood glucose (mmol/L)

8.8 ± 0.4

Fasting C-peptide (pmol/L)

1417 ± 107

eGFR (ml/min/1.73 m2)

83 ± 3

Urine albumine creatinine ratio (mg/g)

42 ± 19

Pro-BNP (pmol/L)

11 ± 3

E/E’

7.4 ± 2